Last reviewed · How we verify
Prohance (GADOTERIDOL)
Prohance (generic name: GADOTERIDOL) is a Paramagnetic Contrast Agent Small molecule drug developed by Bracco. It is currently FDA-approved (first approved 1992).
Prohance works by interacting with magnetic fields to produce detailed images of internal structures.
Prohance (Gadoteridol) is a paramagnetic contrast agent developed by Bracco, used in medical imaging to enhance the visibility of internal structures. It is a small molecule modality that works by interacting with magnetic fields to produce detailed images. Prohance is off-patent and has a single generic manufacturer, approved for use in various medical imaging procedures. The drug has a half-life of 1.6 hours and was FDA-approved in 1992. Key safety considerations include its potential to cause nephrogenic systemic fibrosis in patients with severe kidney impairment.
At a glance
| Generic name | GADOTERIDOL |
|---|---|
| Sponsor | Bracco |
| Drug class | Paramagnetic Contrast Agent |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1992 |
Mechanism of action
Imagine your body is like a city with many buildings and streets. Prohance helps doctors see the city by making the buildings and streets stand out more clearly, allowing them to diagnose and treat medical conditions more effectively.
Approved indications
Boxed warnings
- WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadoteridol injection is not approved for intrathecal use [see Warnings and Precautions ( 5.1 )] . Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired e
Common side effects
- Nephrogenic systemic fibrosis
- Skin induration
- Skin hypertrophy
- Skin tightness
- Contrast media deposition
- Skin fibrosis
- Joint contracture
- Scar
- Joint range of motion decreased
- Anhedonia
- Emotional distress
- Anaphylactic reaction
Key clinical trials
- Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) (EARLY_PHASE1)
- Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (PHASE4)
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems) (PHASE3)
- Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis (PHASE2)
- Intraventricular Stasis In Cardiovascular Disease
- A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems (PHASE3)
- Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases (NA)
- Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prohance CI brief — competitive landscape report
- Prohance updates RSS · CI watch RSS
- Bracco portfolio CI
Frequently asked questions about Prohance
What is Prohance?
How does Prohance work?
Who makes Prohance?
What is the generic name of Prohance?
What drug class is Prohance in?
When was Prohance approved?
What development phase is Prohance in?
What are the side effects of Prohance?
Related
- Drug class: All Paramagnetic Contrast Agent drugs
- Manufacturer: Bracco — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing